Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENCOURAGE-AF)

Daiichi Sankyo

Status

Completed

Conditions

Non-valvular Atrial Fibrillation

Treatments

Drug: Edoxaban

Study type

Observational

Funder types

Industry

Other

Identifiers

NCT04519944

DS-EDO-01-20-DE

Details and patient eligibility

About

This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful percutaneous coronary intervention (PCI) treated with edoxaban.

Full description

The study will assess real-world evidence data of anticoagulation and antiplatelet therapy in patients with NVAF undergoing PCI treated with edoxaban. The observation period will start 4 to 72 hours after removal of the guiding catheter of successful PCI in a hospital and ends 1 year after procedure. Follow-up telephone calls will take place approximately 1 month and 1 year after PCI. Real-world data of effectiveness of edoxaban and antiplatelet therapy, clinical events of interests, safety and quality of life (QoL) data of edoxaban will be collected.

Enrollment

666 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 years of age
Providing written informed consent (ICF) for participation in the study
NVAF treated with edoxaban
Successful PCI
No planned elective cardiac intervention for the whole duration of the study (up to 1 year)
Capability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
Availability of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
Willingness of patients for follow-up by telephone by the site for the whole duration of the study (up to 1 year)
Not simultaneously participating in any interventional study
Life expectancy > 1 year